The economics of benign prostatic hyperplasia treatment: A literature review

Clinical Therapeutics

Volumn 18, Issue 6, 1996, Pages 1227-1241

  Kortt, Michael A ^a,b   Bootman, J Lyle ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PRAZOSIN; TERAZOSIN;

AGED; BALLOON DILATATION; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE SEVERITY; ECONOMICS; HUMAN; IMPOTENCE; MALE; MEDICAL LITERATURE; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; REGRESSION ANALYSIS; REVIEW; TRANSURETHRAL RESECTION; VERTIGO;

EID: 0030512093     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80078-6     Document Type: Article

References (32)

1. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guidelines, Number 8. AHCPR Publication No. 94-0582. Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. February 1994.
2. Tsang KK, Garraway WM. Prostatism and the burden of benign prostatic hyperplasia on elderly men. Age Ageing. 1994;23: 360-364.
3. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1995;22:247-261.
4. Roberts RG. BPH: New guidelines based on symptoms and patient preference. The Agency for Health Care Policy and Research. Geriatrics. 1994;49:24-31.
5. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:495-507.
6. Boyle P. New insights into the epidemiology and natural history of benign prostatic hyperplasia. In: Kurth K, Newling DWW, eds. Benign Prostatic Hyperplasia: Recent Progress in Clinical Research and Practice. New York: Wiley-Liss; 1994:3-18.
7. Carter HB, Coffey DS. The prostate: An increasing medical problem. Prostate. 1990;16:39-48.
8. Wein AJ. Assessing treatment results in benign prostatic hyperplasia. Urol Clin North Am. 1995;22:345-355.
9. Barry MJ, O'Leary MP. The development and clinical utility of symptom scores. Urol Clin North Am. 1995;22:299-307.
10. Boyarsky S, Jones G, Paulson DF, Prout GR. A new look at bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for the investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourinary Surg. 1977;68: 29-32.
11. Madsen PO, Iversen P. A point system for selecting operative candidates. In: Hinman F, ed. Benign Prostatic Hypertrophy. New York: Springer-Verlag; 1983:763-765.
12. Neal DE. Evaluation and results of treatments for prostatism. Urol Res. 1994;22: 61-66.
13. Hillman AL, Schwartz S, Willian MK, et al. The cost effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology. 1996;47:169-178.
14. Bisonni RS, Lawler FH, Holtgrave DR. Transurethral prostatectomy versus transurethral dilatation of the prostatic urethra for benign prostatic hyperplasia: A cost-utility analysis. Fam Pract Res J. 1993;13:25-36.
15. Nording J. Other non-medical treatments: Balloons and stents. In: Kurth K, Newling DWW, eds. Benign Prostatic Hyperplasia: Recent Progress in Clinical Research and Practice. New York: Wiley-Liss; 1994:547-560.
16. Amin EA, Amin M. Comparison of the cost-effectiveness of various therapies for common prostatic disorders. Pharmacoeconomics. 1992;1:357-369.
17. Goluboff ET, Olsson CA. Urologists on a tightrope: Coping with a changing economy. J Urol. 1994;151:1-4.
18. Woodward R, Boyarsky S, Barnett H. Discounting surgical benefits. Enucleation versus resection of the prostate. J Med Syst. 1983;7:481-493.
19. Lowe FC, McDaniel RL, Chmiel JJ, Hillman AL. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology. 1995;46:477-483.
20. Cooper JW, Piepho RW. Cost-effective management of benign prostatic hyperplasia. Drug Benefit Trends. 1995;7:10-33.
21. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1987:1-38.
22. Drummond MF, McGuire AJ, Black NA, et al. Economic burden of treated benign prostatic hyperplasia in the United Kingdom . Br J Urol. 1993;71:290-296.
23. Eri LM, Tveter KJ. Patient recruitment to and cost of a prospective trial of medical treatment for benign prostatic hyperplasia. Eur Urol. 1992;22:9-13.
24. Weis KA, Epstein RS, Huse DM, et al. The costs of prostatectomy for benign prostatic hyperplasia. Prostate. 1993;22:325-334.
25. Roehrborn CG. Some socio-economic issues surrounding prostatectomy: The US experience. In: Kurth K, Newling DWW, eds. Benign Prostatic Hyperplasia: Recent Progress in Clinical Research and Practice. New York: Wiley-Liss; 1994: 419-425.
26. Standaert B, Torfs K. Economics of BPH: Measuring the intangible costs. In: Kurth K, Newling DWW, eds. Benign Prostatic Hyperplasia: Recent Progress in Clinical Research and Practice. New York: Wiley-Liss; 1994:409-418.
27. Scott WG, Scott HM. Annual costs of benign prostatic hyperplasia in New Zealand. Pharmacoeconomics. 1993;4:455-468.
28. Baladi JF, Menon D, Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics. 1996;9:443-454.
29. Chirikos TN, Sanford E. Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia. J Urol. 1996;155:1311-1316.
30. Drummond MF. Cost-of-illness studies. A major headache? Pharmacoeconomics. 1992;2:1-4.
31. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin Ther. 1994;16:715-730.
32. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res. 1995;23: 395-412.